The Discovery and Development of a Novel Vaccine to Protect against Neisseria meningitidis Serogroup B Disease

References

• Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983; 2:355 - 7; http://dx.doi.org/10.1016/S0140-6736(83)90340-9; PMID: 6135869
   PubMed Web of Science ®Google Scholar
• Milagres LG, Ramos SR, Sacchi CT, Melles CE, Vieira VS, Sato H, Brito GS, Moraes JC, Frasch CE. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 1994; 62:4419 - 24; PMID: 7927704
   PubMed Web of Science ®Google Scholar
• Wong SH, Lennon DR, Jackson CM, Stewart JM, Reid S, Ypma E, O’Hallahan JM, Oster P, Mulholland K, Martin DR. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr Infect Dis J 2009; 28:385 - 90; http://dx.doi.org/10.1097/INF.0b013e318195205e; PMID: 19384263
   PubMed Web of Science ®Google Scholar
• Bjune G, Høiby EA, Grønnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nøkleby H, Rosenqvist E, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093 - 6; http://dx.doi.org/10.1016/0140-6736(91)91961-S; PMID: 1682541
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine 2005; 23:2222 - 7; http://dx.doi.org/10.1016/j.vaccine.2005.01.051; PMID: 15755600
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010; 107:19490 - 5; http://dx.doi.org/10.1073/pnas.1013758107; PMID: 20962280
   PubMed Web of Science ®Google Scholar
• Danve B, Guinet F, Boutry E, Speck D, Cadoz M, Nassif X, et al. Safety and immunogenicity of a Neisseria meningitidis group B transferrin binding protein vaccine in adults. In: Nassif MJQM, Taha MK, ed. Eleventh International Pathogenic Neisseria Conference. Paris, France, 1998; p53.
   Google Scholar
• Moe GR, Tan S, Granoff DM. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 1999; 67:5664 - 75; PMID: 10531214
   PubMed Web of Science ®Google Scholar
• Sacchi CT, Whitney AM, Popovic T, Beall DS, Reeves MW, Plikaytis BD, Rosenstein NE, Perkins BA, Tondella ML, Mayer LW. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000; 182:1169 - 76; http://dx.doi.org/10.1086/315833; PMID: 10979914
   PubMed Web of Science ®Google Scholar
• Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden MC. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 2004; 72:5955 - 62; http://dx.doi.org/10.1128/IAI.72.10.5955-5962.2004; PMID: 15385499
   PubMed Web of Science ®Google Scholar
• Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, Schmink S, Muzzi A, Bambini S, Rappuoli R, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 2011; 29:4739 - 44; http://dx.doi.org/10.1016/j.vaccine.2011.04.092; PMID: 21571026
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006; 103:10834 - 9; http://dx.doi.org/10.1073/pnas.0603940103; PMID: 16825336
   PubMed Web of Science ®Google Scholar
• Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, Ooi P, Smith RP, Weise P, Wetherell M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004; 72:2088 - 100; http://dx.doi.org/10.1128/IAI.72.4.2088-2100.2004; PMID: 15039331
   PubMed Web of Science ®Google Scholar
• Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, Ngampasutadol J, Vogel U, Granoff DM, Ram S. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006; 177:501 - 10; http://dx.doi.org/10.4049/jimmunol.177.1.501; PMID: 16785547
   PubMed Web of Science ®Google Scholar
• Welsch JA, Ram S, Koeberling O, Granoff DM. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 2008; 197:1053 - 61; http://dx.doi.org/10.1086/528994; PMID: 18419542
   PubMed Web of Science ®Google Scholar
• Seib KL, Serruto D, Oriente F, Delany I, Adu-Bobie J, Veggi D, Aricò B, Rappuoli R, Pizza M. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 2009; 77:292 - 9; http://dx.doi.org/10.1128/IAI.01071-08; PMID: 18852235
   PubMed Web of Science ®Google Scholar
• Konar M, Granoff DM, Beernink PT. Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J Infect Dis 2013; 208:627 - 36; http://dx.doi.org/10.1093/infdis/jit239; PMID: 23715659
   PubMed Web of Science ®Google Scholar
• Giuntini S, Reason DC, Granoff DM. Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun 2011; 79:3751 - 9; http://dx.doi.org/10.1128/IAI.05182-11; PMID: 21708990
   PubMed Web of Science ®Google Scholar
• Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010; 28:6086 - 93; http://dx.doi.org/10.1016/j.vaccine.2010.06.083; PMID: 20619376
   PubMed Web of Science ®Google Scholar
• Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009; 200:379 - 89; http://dx.doi.org/10.1086/600141; PMID: 19534597
   PubMed Web of Science ®Google Scholar
• Beernink PT, Granoff DM. The modular architecture of meningococcal factor H-binding protein. Microbiology 2009; 155:2873 - 83; http://dx.doi.org/10.1099/mic.0.029876-0; PMID: 19574307
   PubMed Web of Science ®Google Scholar
• Hoiseth SK, Murphy E, Andrew L, Vogel U, Frosch M, Hellenbrand W, Abad R, Vazquez JA, Borrow R, Findlow J, et al. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr Infect Dis J 2013; 32:1096 - 101; http://dx.doi.org/10.1097/INF.0b013e31829aa63b; PMID: 23694830
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, Medini D, Tsang R, members of the Canadian Immunization Monitoring Program, Active (IMPACT). Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 2013; 32:124 - 30; http://dx.doi.org/10.1016/j.vaccine.2013.03.063; PMID: 23588089
   PubMed Web of Science ®Google Scholar
• Ala’aldeen DA, Flint M, Oldfield NJ, Omer SA, McNeil LK, Jiang Q, Murphy E, Giardina PC, Novikova EG, Dodge-Scully IL, et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine 2010; 28:7667 - 75; http://dx.doi.org/10.1016/j.vaccine.2010.09.038; PMID: 20875489
   PubMed Web of Science ®Google Scholar
• Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27:Suppl 2 B112 - 6; http://dx.doi.org/10.1016/j.vaccine.2009.04.065; PMID: 19464093
   PubMed Web of Science ®Google Scholar
• Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058 - 66; PMID: 11287977
   PubMed Web of Science ®Google Scholar
• McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris SL, Scott AA, Tan C, Mack M, DaSilva I, Alexander K, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009; 27:3417 - 21; http://dx.doi.org/10.1016/j.vaccine.2009.01.075; PMID: 19200847
   PubMed Web of Science ®Google Scholar
• Richmond PC, Nissen MD, Marshall HS, Lambert SB, Roberton D, Gruber WC, Jones TR, Arora A. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine 2012; 30:6163 - 74; http://dx.doi.org/10.1016/j.vaccine.2012.07.065; PMID: 22871351
   PubMed Web of Science ®Google Scholar
• Vesikari T, Diez-Domingo J, Ostergaard L, Beeslaar J, Eiden J, Jiang Q, et al. Safety and immunogenicity of an investigational meningococcal serogroup B bivalent rLP2086 vaccine in healthy adolescents. 32nd Annual ESPID Meeting. Dublin, Ireland, 2014.
   Google Scholar
• Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Beeslaar J, Szenborn L, Wysocki J, et al, 2001 Study Investigators. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12:597 - 607; http://dx.doi.org/10.1016/S1473-3099(12)70087-7; PMID: 22569484
   PubMed Web of Science ®Google Scholar
• Nissen MD, Marshall HS, Richmond PC, Jiang Q, Harris SL, Jones TR, Jansen KU, Perez JL. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J 2013; 32:364 - 71; http://dx.doi.org/10.1097/INF.0b013e31827b0d24; PMID: 23114369
   PubMed Web of Science ®Google Scholar
• Marshall HS, Richmond PC, Nissen MD, Jiang Q, Anderson AS, Jansen KU, Reynolds G, Ziegler JB, Harris SL, Jones TR, et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J 2012; 31:1061 - 8; PMID: 22718089
   PubMed Web of Science ®Google Scholar
• Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, Jiang Q, Anderson AS, Jones TR, Harris SL, Jansen KU, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 2013; 31:1569 - 75; http://dx.doi.org/10.1016/j.vaccine.2013.01.021; PMID: 23352429
   PubMed Web of Science ®Google Scholar
• Sheldon EA, Schwartz H, Jiang Q, Giardina PC, Perez JL. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother 2012; 8:888 - 95; http://dx.doi.org/10.4161/hv.19983; PMID: 22832260
   PubMed Web of Science ®Google Scholar
• Pfizer. Press release anouncing the designation of breakthrough therapy by the FDA to bivalent rLP2086, 2014
   Google Scholar
• Pfizer. Press release anouncing the completion of the submission of the biological license application for the licensure of bivalent rLP2086, 2014
   Google Scholar
• Bröker M. Indirect effects by meningococcal vaccines: herd protection versus herd immunity. Hum Vaccin 2011; 7:881 - 2; http://dx.doi.org/10.4161/hv.7.8.16273; PMID: 21785283
   PubMed Web of Science ®Google Scholar
• Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, Brunelli B, Pieri A, Santini L, Savino S, et al. Vaccination against NeisZseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003; 197:789 - 99; http://dx.doi.org/10.1084/jem.20021911; PMID: 12642606
   PubMed Web of Science ®Google Scholar